FR20C1016I2 - RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS - Google Patents

RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS

Info

Publication number
FR20C1016I2
FR20C1016I2 FR20C1016C FR20C1016C FR20C1016I2 FR 20C1016 I2 FR20C1016 I2 FR 20C1016I2 FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 I2 FR20C1016 I2 FR 20C1016I2
Authority
FR
France
Prior art keywords
vesicular stomatitis
stomatitis virus
against viral
viral hemorrhagic
recombinant vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1016C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canada Minister of Health
Original Assignee
Canada Minister of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canada Minister of Health filed Critical Canada Minister of Health
Publication of FR20C1016I1 publication Critical patent/FR20C1016I1/fr
Application granted granted Critical
Publication of FR20C1016I2 publication Critical patent/FR20C1016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Recombinant VSV viral particles and the use thereof as vaccines for immunization are described.
FR20C1016C 2002-07-26 2020-05-06 RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS Active FR20C1016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39855202P 2002-07-26 2002-07-26
PCT/CA2003/001125 WO2004011488A2 (en) 2002-07-26 2003-07-28 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

Publications (2)

Publication Number Publication Date
FR20C1016I1 FR20C1016I1 (en) 2020-06-12
FR20C1016I2 true FR20C1016I2 (en) 2022-04-01

Family

ID=31188416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1016C Active FR20C1016I2 (en) 2002-07-26 2020-05-06 RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS

Country Status (9)

Country Link
US (1) US8012489B2 (en)
EP (1) EP1527087B2 (en)
AT (1) ATE455124T1 (en)
AU (1) AU2003250680A1 (en)
CA (1) CA2493142C (en)
DE (1) DE60330966D1 (en)
ES (1) ES2338416T5 (en)
FR (1) FR20C1016I2 (en)
WO (1) WO2004011488A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217328A1 (en) * 2007-12-18 2011-09-08 Trustees Of Boston University Compositions and methods for treating ebola virus infection
EP2245154A4 (en) * 2007-12-18 2012-12-05 Univ Boston Pre-or post-exposure treatment for filovirus or arenavirus infection
WO2010048615A2 (en) * 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
BRPI1009616B8 (en) * 2009-06-08 2021-05-25 Univ Western Ontario immunization platform for use in a prime-boost immunization strategy and kit
WO2012170814A1 (en) * 2011-06-08 2012-12-13 The Ohio State University Norovirus immunogens and related materials and methods
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
US20200181678A1 (en) * 2016-12-15 2020-06-11 Merck Sharp & Dohme Corp. Cell-Based Reporter Assay for Live Virus Vaccines
KR20200096904A (en) * 2017-09-15 2020-08-14 오하이오 스테이트 이노베이션 파운데이션 Vaccines for the prevention of respiratory syncytial virus (RSV) infection and methods of making and using vaccines
US11274282B2 (en) 2019-05-15 2022-03-15 Board Of Regents, The University Of Texas System Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
CN116075725A (en) 2020-04-17 2023-05-05 瑞泽恩制药公司 Assay for coronavirus neutralizing antibodies
WO2021212101A1 (en) * 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
CN117925662B (en) * 2023-12-19 2024-08-13 军事科学院军事医学研究院军事兽医研究所 Construction method of recombinant vesicular stomatitis virus and Ebola hemorrhagic fever infection animal model

Also Published As

Publication number Publication date
EP1527087B2 (en) 2013-07-17
ATE455124T1 (en) 2010-01-15
WO2004011488A9 (en) 2004-06-03
WO2004011488A3 (en) 2004-04-15
AU2003250680A8 (en) 2004-02-16
DE60330966D1 (en) 2010-03-04
CA2493142A1 (en) 2004-02-05
FR20C1016I1 (en) 2020-06-12
US20060193872A1 (en) 2006-08-31
US8012489B2 (en) 2011-09-06
EP1527087A2 (en) 2005-05-04
EP1527087B1 (en) 2010-01-13
CA2493142C (en) 2013-11-12
WO2004011488A2 (en) 2004-02-05
AU2003250680A1 (en) 2004-02-16
ES2338416T3 (en) 2010-05-07
ES2338416T5 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
FR20C1016I2 (en) RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS
IL238584B (en) High titer recombinant influenza viruses for vaccines and gene therapy
HK1214298A1 (en) Recombinant influenza viruses for vaccines and gene therapy
IL163646A0 (en) Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
UA85536C2 (en) Viral antigens
EP1622574A4 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
HK1127370A1 (en) Mutant vesicular stomatitis viruses and use thereof
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
IS7830A (en) Hepatitis C virus (HCV) vaccine
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
AU2003256912A8 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
IL176500A (en) Use of a virion of a respiratory syncytial virus with a mutation in the gene encoding for the g attachment protein for the prevention or treatment of a pneumoviral infection
AU2003279240A8 (en) Methods for purifying viral particles for gene therapy
AR004464A1 (en) A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
EP1485488A4 (en) Recombinant negative strand virus rna expression systems and vaccines
BR0310020A (en) Expression of genes in modified vaccinia virus ankara by use of vaccinia ati promoter
ATE408013T1 (en) INFECTIOUS CDNA CLONE OF GB VIRUS B AND ITS USES
EP1439856A4 (en) Recombinant rabies vaccine and methods of preparation and use
AU2002318104A1 (en) Microparticles and methods for delivery of recombinant viral vaccines
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
TR200201954T2 (en) Medicinal substances for viral diseases.
GB0213446D0 (en) Methods for making recombinant viruses and vaccines
AUPR374701A0 (en) Sequestration of blood borne viral particles
AUPR442501A0 (en) Sequestration of blood borne viral particles